Can NOAH guide us to improved survival in breast cancer?
Mené sur 235 patientes atteintes d'un cancer du sein HER2+ inflammatoire ou de stade localement avancé, cet essai de phase III évalue l'efficacité à long terme (durée médiane de suivi : 5,4 ans) d'un traitement néoadjuvant comprenant du trastuzumab suivi d'un traitement adjuvant à l'aide de trastuzumab
Introduction of adjuvant therapy with the monoclonal antibody trastuzumab has been the most significant advance in the management of women with early stage HER2-positive breast cancer, with improvement of disease-free and overall survival in these patients with a biologically aggressive subtype of the disease. For patients with large operable or locally advanced breast cancer, induction (neoadjuvant) chemotherapy is a standard approach. The NOAH trial...
The Lancet Oncology , commentaire, 2013